| scholarly article | Q13442814 |
| P50 | author | Guido Cavaletti | Q56426747 |
| P2093 | author name string | N Colombo | |
| A Lissoni | |||
| D Franchi | |||
| M Piatti | |||
| L Marzorati | |||
| G Bogliun | |||
| F Fei | |||
| A Buda | |||
| A Zincone | |||
| C Zanna | |||
| M T La Presa | |||
| S Cundari | |||
| P433 | issue | 9 | |
| P921 | main subject | toxic encephalopathy | Q7830379 |
| cisplatin | Q412415 | ||
| paclitaxel | Q423762 | ||
| chemotherapy | Q974135 | ||
| neurotoxicity | Q3338704 | ||
| P304 | page(s) | 1439-1442 | |
| P577 | publication date | 2004-09-01 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy | |
| P478 | volume | 15 |
| Q48454566 | 15th Annual Meeting of the Safety Pharmacology Society: Focus on traditional sensory systems |
| Q37091093 | A systematic review of experimental and clinical acupuncture in chemotherapy-induced peripheral neuropathy |
| Q36244607 | Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma. |
| Q58874394 | Chemotherapy-Induced Neuropathy |
| Q33889319 | Chemotherapy-Induced Peripheral Neuropathy in Pediatric Cancer Patients |
| Q43058277 | Chemotherapy-induced peripheral neuropathy: an unresolved issue |
| Q60750355 | Chemotherapy-induced peripheral neurotoxicity |
| Q51000217 | Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale. |
| Q30818191 | Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNomS study. |
| Q41475920 | Depletion of nerve growth factor in chemotherapy-induced peripheral neuropathy associated with hematologic malignancies |
| Q50797877 | Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. |
| Q42750577 | Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy. |
| Q36350645 | Effect of Vitamin E on Oxaliplatin-induced Peripheral Neuropathy Prevention: A Randomized Controlled Trial |
| Q37036780 | Health-related quality of life in ovarian cancer patients and its impact on clinical management |
| Q51939446 | Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. |
| Q36884527 | Nerve growth factor alters microtubule targeting agent-induced neurotransmitter release but not MTA-induced neurite retraction in sensory neurons |
| Q36526946 | Nerve growth factor: from the early discoveries to the potential clinical use |
| Q36458738 | Neurologic toxicities of cancer therapies |
| Q30361070 | Neurotoxicity in ovarian cancer patients on Gynecologic Oncology Group (GOG) protocol 218: characteristics associated with toxicity and the effect of substitution with docetaxel: an NRG Oncology/Gynecologic Oncology Group study. |
| Q28084413 | Neurotrophins and Neuropathic Pain: Role in Pathobiology |
| Q54960570 | Pain in cancer survivors. |
| Q85246920 | Palliative Care for Adults Across the Cancer Trajectory: From Diagnosis to End of Life |
| Q37399781 | Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN). |
| Q36344699 | Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention |
| Q40445771 | Peripheral neuropathy induced by administration of cisplatin- and paclitaxel-based chemotherapy. Could it be predicted? |
| Q37118862 | Platinum neurotoxicity pharmacogenetics |
| Q43496569 | Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity |
| Q84785194 | Precise evaluation of chemotherapy-induced peripheral neuropathy using the visual analogue scale: a quantitative and comparative analysis of neuropathy occurring with paclitaxel-carboplatin and docetaxel-carboplatin therapy |
| Q90579043 | Prediction of Chemotherapy-Induced Peripheral Neuropathy in Patients with Lymphoma and Myeloma: the Roles of Brain-Derived Neurotropic Factor Protein Levels and A Gene Polymorphism |
| Q93073304 | Prevalence and Predictors of Cisplatin-Induced Peripheral Neuropathy at the Kenyatta National Hospital |
| Q34303792 | Profound and persistent painful paclitaxel peripheral neuropathy in a premenopausal patient |
| Q35210260 | Retinoic acid reduces chemotherapy-induced neuropathy in an animal model and patients with lung cancer |
| Q47552411 | Risk-reduction and treatment of chemotherapy-induced peripheral neuropathy |
| Q37808196 | Role of Erythropoeitin in Prevention of Chemotherapy-induced Peripheral Neuropathy |
| Q38674146 | Selected Risk Nutritional Factors for Chemotherapy-Induced Polyneuropathy |
| Q90471812 | Subclinical Peripheral Neuropathy in Patients with Head and Neck Cancer: A Quantitative Sensory Testing (QST) Study |
| Q36893299 | Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy |
| Q37086010 | Supportive care for women with gynecologic cancers |
| Q89622489 | Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Unsuitable to Receive Cisplatin-Based Therapy |
Search more.